R-BIOPHARM ANALYSIS SYSTEMS TRADING (BEIJING) CO., LTD.

Booth number 2P32

r-biopharm.com/

About us

R-Biopharm is a leading developer of test solutions for clinical diagnostics and food & feed analysis. In both sectors, the R-Biopharm test kits offer high precision and accuracy, key requirements where patient and consumer health is at risk.

Today the German parent company R-Biopharm is represented by subsidiaries in the UK, USA, Italy, France, Latin America, Brazil, Spain, Australia and China as well as by a worldwide extensive network of more than 80 distributors.In clinical diagnostics, R-Biopharm possesses many years of experience, particularly in the field of autoimmune disease dianostics, infectious stool diagnostics as well as in the field of serological infection diagnostics and allergy diagnostics.

R-Biopharm has been a successful player worldwide and is constantly developing new and groundbreaking test systems in the different areas. In this process, automation is a main focus. All tests are validated and CE-marked.

Products and services

R-Biopharm is a leading developer of test solutions for clinical diagnostics and food & feed analysis.

RIDASCREEN®, RIDA®, PREP®, EASI EXTRACT, and PentoCheck® were worldwide recognized trademarks of R-Biopharm. Today the German parent company R-Biopharm is represented by subsidiaries in nearly 30 countries as well as by a worldwide extensive network of 122 distributors. All tests are validated and CE-marked. Right now R-Biopharm represent high quality in the field of food and feed analysis in China.

In clinical diagnostics, R-Biopharm possesses many years of experience, particularly in the field of autoimmune disease dianostics, companion diagnostics (Therapeutic Drug Monitoring in Gastroenterology), allergy diagnostics, infectious diseases, gastroenterology, molecular diagnosis and IVD reagents (antibody, substrates, conjugates and stabilizers). R-Biopharm has been a successful player worldwide and is constantly developing new and groundbreaking test systems in the different areas.

SeraSpot®

R-Biopharm offers you a new product line: SeraSpot®, the new microspot array for multiplex diagnostics of autoimmune diseases.
Autoantibody testing is a central element in the diagnosis and treatment of AID. R-Biopharm offers SeraSpot®, a new microspot array for the diagnosis of autoimmune and infectious diseases. Today, the SeraSpot® platform comprises 4 different microspot arrays plus the microspot array scanner for the diagnosis of AID.

Further reading

therapeutic drug monitoring of Infliximab and Adalimumab

With our ELISA and lateral flow test for therapeutic drug monitoring, you can check the drug concentration in the patient’s blood to adjust the dosage of the individual needs of the patient.In order for TNFα blockers to work optimally, it is important to check their trough level on a regular basis, since the bioavailability differs from person to person. Monitoring of drug and anti-drug antibody-levels of TNFα blockers helps to optimally adjust the therapy to the individual needs of the patient.

Further reading

Seraline®

Recombinant antigens of diagnostic importance as well as control bands are plotted on nitrocellulose membranes. After blocking remaining free protein binding sites the membrane is cut into strips. The result interpretation of the developed strips is realized by comparison of the band pattern with a lot specific template. Alternatively the strips can be evaluated with the Seraline®scan software.

Address
R-BIOPHARM ANALYSIS SYSTEMS TRADING (BEIJING) CO., LTD.
Suite 1903, Office Building A, No.6 Futong East Avenue, Chaoyang District
100102 Beijing
P. R. China

Phone: +86 10 84583218
Fax: +86 10 84580691
Internet: r-biopharm.com/
E-mail: Send message

Contact person

Qi
Clinic Marketing Manager
Phone: +86 13 811525314
E-mail: Send message

News & Innovations

Cooperation between Pfizer Germany and R-Biopharm Inflammatory Bowel Diseases (IBD): Infliximab Rapid Test Makes Possible Direct and Individual Therapy Optimization

Berlin, Darmstadt, March 19, 2018 – Pfizer and R-Biopharm concluded a cooperation agreement at the beginning of the year. The agreement centers on the RIDA®QUICK IFX Monitoring infliximab rapid test developed by R-Biopharm. Physicians can use this rapid test to check the infliximab trough concentrations of their IBD patients directly at the point of care within 20minutes and adjust the infliximab dose, if needed. Pfizer offers the RIDA®QUICK IFX Monitoring test to gastroenterology, internists, and IBD specialty practices, giving physicians an innovative option for performing therapeutic drug monitoring in the doctor´s office.

Smart idea with high performance: Microspot arrays revolutionize clinical diagnostics

Microspot arrays facilitate efficient and high-quality multiplex diagnostics for any sample throughput. They are also convenient, flexible, and automatable. This innovative technology is available now in the practical ELISA format from R-Biopharm with its SeraSpot® product line.
Microarrays are modern diagnostics tests that can analyze a wide range of parameters simultaneously and require only a small amount of sample material to do so. They can be used for many applications in medicine, genetics, or molecular biology. The new SeraSpot® system combines this exciting technology with established and convenient ELISA processing. The tests have different antigens that are fixed (spotted) to the bottom of every well in the microtiter plate. Flexible solution for small and large laboratories.

Click here if you notice an image that violates copyright or privacy rights.

Get in contact